Neratinib plus Trastuzumab Is Superior to Pertuzumab plus Trastuzumab in HER2-Positive Breast Cancer Xenograft Models

Researchers established the efficacy of combining neratinib (N) with trastuzumab (T) and support clinical testing to investigate the efficacy of N + T with or without chemotherapy in the neoadjuvant setting for HER2+ breast cancer.